Recent Updates
Recently added Catalysts
KNSA Positive Sentiment Score: 60/100

Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024

Key Takeaway: Kiniksa Pharmaceuticals International, plc will release its second quarter 2024 financial results and discuss its portfolio execution on July 23, 2024. The company will host a conference call and live webcast at 8:30 a.m. Eastern Time. Interested participants can register for the call and access a replay of the event shortly after it concludes. Kiniksa is focused on developing therapies for serious diseases with unmet medical needs, highlighting its immune-modulating assets.

Market Sentiment Analysis

POSITIVE FACTORS

  • Kiniksa Pharmaceuticals will report its financial results, indicating ongoing activities and updates.
  • The company has a portfolio targeting significant unmet medical needs and offers differentiated therapeutic options.

Full Press Release Details

LONDON, July 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, July 23, 2024 at 8:30 a.m. Eastern Time to report its second quarter 2024 financial results and recent portfolio execution.
A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
Every Second Counts! ®
Kiniksa Investor and Media Contact

Frequently Asked Questions

When will Kiniksa report its Q2 2024 financial results?

Kiniksa will report its Q2 2024 financial results on July 23, 2024.

How can I access the Kiniksa conference call?

You can access the conference call via the Investors & Media section of Kiniksa's website.

Will there be a replay of the conference call?

Yes, a replay will be available on Kiniksa’s website within 48 hours after the event.

What conditions does Kiniksa's portfolio target?

Kiniksa targets underserved cardiovascular and autoimmune conditions.

What is ARCALYST®?

ARCALYST® is Kiniksa's immune-modulating asset for treating certain diseases.

Last updated: Jul 16, 2024